U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07560475) titled 'Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients' on April 20.
Brief Summary: An Exploratory Study on the Efficacy and Safety of Different Administration Routes of SHR-A1811 in the Treatment of HER2-Positive Advanced Breast Cancer
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
HER2positive
Advanced Breast Cancer
HER2 + Breast Cancer
Intervention:
DRUG: SHR-A1811
SHR-A1811 administered weekly
DRUG: SHR-A1811
SHR-A1811 administered every two weeks (q2w)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Disclaimer: Curated by...